Skip to main content
. 2017 Jul 4;8(40):67904–67917. doi: 10.18632/oncotarget.18958

Figure 1. The EGFR pathway regulates the IBC cell population that expresses CSC markers.

Figure 1

(A) EGFR expression is depleted in SUM149 cells after EGFR knockdown. Expression of EGFR in the stable shCtrl clone and EGFR knockdown clones, shEGFR-1 and shEGFR-3, was analyzed by Western blotting. (B) EGFR depletion reduces the formation of mammospheres in SUM149 cells. Bars, ± SD. *P < 0.001. (C and D). EGFR depletion decreases the CD44+/CD24−/low population (C) and ALDH activity (D) of SUM149 cells. *P < 0.001; **P < 0.01. (E) Erlotinib treatment decreases mammosphere formation of SUM149 cells. Shown are representative images of primary mammospheres. *P < 0.001; **P = 0.001. (F) and (G) Erlotinib treatment decreases the CD44+/CD24−/low population (F) and ALDH activity (G) of SUM149 cells. FITC, fluorescein isothiocyanate; PE, phycoerythrin. *P < 0.01. (H) Panitumumab (PmAb) treatment inhibits EGF-stimulated phosphorylation of EGFR in SUM149 cells. Cells were pretreated with PmAb at the indicated doses for 1 hour and then stimulated with EGF (50 ng/mL) for 15 minutes. (I) PmAb treatment decreases the CD44+/CD24−/low population of SUM149 cells. (J) PmAb treatment decreases the mammosphere formation of SUM149 cells. *P < 0.001; **P < 0.005. Experiments were independently repeated 3 times.